Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base

The Lancet Respiratory Medicine

Volumn 8, Issue 6, 2020, Pages 539-541

  Taccone, Fabio S ^a   Gorham, Julie ^a   Vincent, Jean Louis ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CHLOROQUINE; HYDROXYCHLOROQUINE;

ACUTE RESPIRATORY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; ALKALINIZATION; ANTIVIRAL THERAPY; ARTIFICIAL VENTILATION; BLOOD OXYGEN TENSION; CHINA; CLINICAL OUTCOME; COMPUTER ASSISTED TOMOGRAPHY; CORONAVIRUS DISEASE 2019; CRITICALLY ILL PATIENT; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; EVIDENCE BASED PRACTICE; FEVER; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPOXEMIA; IN VITRO STUDY; INTENSIVE CARE UNIT; INTENSIVIST; KIDNEY FAILURE; LENGTH OF STAY; LIVER DYSFUNCTION; LUNG LAVAGE; LUNG LESION; MORTALITY RATE; MULTIPLE ORGAN FAILURE; NOTE; PHAGOLYSOSOME; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; THROAT CULTURE; TREATMENT DURATION; VIRAL CLEARANCE; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION; VIRUS VIRULENCE; BETACORONAVIRUS; CORONAVIRUS INFECTION; DRUG REPOSITIONING; EVIDENCE BASED MEDICINE; HEALTH SERVICE; PANDEMIC; VIROLOGY; VIRUS PNEUMONIA;

BETACORONAVIRUS; CORONAVIRUS INFECTIONS; DRUG REPOSITIONING; EVIDENCE-BASED MEDICINE; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; HYDROXYCHLOROQUINE; PANDEMICS; PNEUMONIA, VIRAL;

EID: 85083653004     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(20)30172-7     Document Type: Note

References (14)

1. Yang, X, Yu, Y, Xu, J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med, 2020 published online Feb 24. https://doi.org/10.1016/S2213-2600(20)30079-5.
2. Simonis, FD, Serpa, NA, Binnekade, JM, et al. Effect of a low vs intermediate tidal volume strategy on ventilator-free days in intensive care unit patients without ARDS: a randomized clinical trial. JAMA 320 (2018), 1872–1880.
3. Yao, X, Ye, F, Zhang, M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis, 2020 published online March 9. DOI:10.1093/cid/ciaa237.
4. Liu, J, Cao, R, Xu, M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov, 6, 2020, 16.
5. Wang, M, Cao, R, Zhang, L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30 (2020), 269–271.
6. Gao, J, Tian, Z, Yang, X, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14 (2020), 72–73.
7. Cortegiani, A, Ingoglia, G, Ippolito, M, Giarratano, A, Einav, S, A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care, 2020 published online March 10. DOI:10.1016/j.jcrc.2020.03.005.
8. Gautret, P, Lagier, JC, Parola, P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents, 2020 published online March 20. DOI:10.1016/j.ijantimicag.2020.105949.
9. Gautret, P, Lagier, JC, Parola, P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study. https://www.mediterranee-infection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf, 2020. (Accessed 2 April 2020)
10. Alhazzani, W, Moller, MH, Arabi, YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med, 2020 published online March 28. DOI:10.1007/s00134-020-06022-5.
11. Guan, WJ, Ni, ZY, Hu, Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 2020 published online Feb 28. DOI:10.1056/NEJMoa2002032.
12. Chen, J, Liu, D, Liu, L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci), 2020 published online March 6. DOI:10.3785/j.issn.1008-9292.2020.03.03.
13. Chen, Z, Hu, J, Zhang, Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv, 2020 published online March 31. DOI: 10.1101/2020.03.22.20040758 (preprint).
14. Molina, JM, Delaugerre, C, Le Goff, J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect, 2020 published online March 30. DOI:10.1016/j.medmal.2020.03.006.